Head-to-head evidence
DD01 vs TE-8105
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
DD01
Developed by D&D Pharmatech and partners
NCT06410924 · Phase 2 · completed
This randomized, triple-blind, placebo-controlled Phase 2 trial enrolled 67 people with fatty liver disease and measured the proportion who achieved at least a 30% reduction in liver fat, measured by MRI scan, after 12 weeks. DD01 met this imaging-based endpoint far more often than placebo (75.8% vs 11.8%), though liver-fat reduction on imaging is an earlier marker of benefit rather than the biopsy-confirmed liver-disease improvement that later-stage trials assess.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
TE-8105
Developed by Immunwork
NCT06471530 · Phase 1/2 · completed
This was an open-label, non-randomized, dose-escalation study with no placebo or control group, so it cannot show whether any effect is attributable to the drug itself. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DD01's landscape · TE-8105's landscape